Strategies for the Discovery of Target-Specific or Isoform-Selective Modulators.
暂无分享,去创建一个
Peng Zhan | Yukihiro Itoh | Takayoshi Suzuki | P. Zhan | Xinyong Liu | Yukihiro Itoh | Takayoshi Suzuki | Xinyong Liu
[1] S. Laufer,et al. Solution-phase parallel synthesis of ruxolitinib-derived Janus kinase inhibitors via copper-catalyzed azide-alkyne cycloaddition. , 2015, ACS combinatorial science.
[2] S. Knapp,et al. Selective Bisubstrate Inhibitors with Sub‐nanomolar Affinity for Protein Kinase Pim‐1 , 2013, ChemMedChem.
[3] A. Becker,et al. Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases. , 2013, Journal of medicinal chemistry.
[4] E. Lionta,et al. Structure-Based Virtual Screening for Drug Discovery: Principles, Applications and Recent Advances , 2014, Current topics in medicinal chemistry.
[5] R. Morphy. Selectively nonselective kinase inhibition: striking the right balance. , 2010, Journal of medicinal chemistry.
[6] Juswinder Singh,et al. Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3Kα. , 2013, Journal of medicinal chemistry.
[7] Takayoshi Suzuki,et al. An unexpected example of protein-templated click chemistry. , 2010, Angewandte Chemie.
[8] Bisubstrate Inhibitors of Protein Kinases: from Principle to Practical Applications , 2010, ChemMedChem.
[9] S. Shuto,et al. Conformationally Restricted GABA with Bicyclo[3.1.0]hexane Backbone as the First Highly Selective BGT-1 Inhibitor. , 2014, ACS medicinal chemistry letters.
[10] B. Shoichet,et al. Molecular docking and ligand specificity in fragment-based inhibitor discovery. , 2009, Nature chemical biology.
[11] R. Bhat,et al. Progress in the discovery and development of heat shock protein 90 (Hsp90) inhibitors. , 2014, Journal of medicinal chemistry.
[12] Takayoshi Suzuki,et al. An Overview of Phenylcyclopropylamine Derivatives: Biochemical and Biological Significance and Recent Developments , 2013, Medicinal research reviews.
[13] Hiroki Tsumoto,et al. Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries. , 2012, Journal of medicinal chemistry.
[14] Johannes C. Hermann,et al. Discovery of a series of novel 5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers, as potent JAK3 kinase inhibitors. , 2013, Bioorganic & medicinal chemistry letters.
[15] Peng Zhan,et al. Recent advances in the structure-based rational design of TNKSIs. , 2014, Molecular bioSystems.
[16] Michelle S. Miller,et al. L-Aminoacyl-triazine derivatives are isoform-selective PI3Kβ inhibitors that target non-conserved Asp862 of PI3Kβ , 2013, ACS medicinal chemistry letters.
[17] Johannes C. Hermann,et al. Rational design of highly selective spleen tyrosine kinase inhibitors. , 2012, Journal of medicinal chemistry.
[18] R. Liskamp,et al. Cell-penetrating bisubstrate-based protein kinase C inhibitors. , 2013, ACS chemical biology.
[19] Makoto Hasegawa,et al. Identification of cell-active lysine specific demethylase 1-selective inhibitors. , 2009, Journal of the American Chemical Society.
[20] Vinicius M Alves,et al. Virtual screening strategies in medicinal chemistry: the state of the art and current challenges. , 2014, Current topics in medicinal chemistry.
[21] T. Steinmetzer,et al. A new strategy for the development of highly potent and selective plasmin inhibitors. , 2012, Journal of medicinal chemistry.
[22] Gary Box,et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer . , 2008, Journal of medicinal chemistry.
[23] Heejun Kim,et al. Privileged structures: efficient chemical "navigators" toward unexplored biologically relevant chemical spaces. , 2014, Journal of the American Chemical Society.
[24] Michael J. Munson,et al. Characterization of VPS34-IN1, a selective inhibitor of Vps34, reveals that the phosphatidylinositol 3-phosphate-binding SGK3 protein kinase is a downstream target of class III phosphoinositide 3-kinase , 2014, The Biochemical journal.
[25] C. Nicchitta,et al. Development of a Grp94 inhibitor. , 2012, Journal of the American Chemical Society.
[26] S. Haggarty,et al. Kinetically selective inhibitors of histone deacetylase 2 (HDAC2) as cognition enhancers , 2014, Chemical science.
[27] C. Bountra,et al. Epigenetic protein families: a new frontier for drug discovery , 2012, Nature Reviews Drug Discovery.
[28] Charles R. Holst,et al. Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitors. , 2012, Journal of medicinal chemistry.
[29] J. Lisztwan,et al. Structural definitions of Jumonji family demethylase selectivity. , 2015, Drug discovery today.
[30] B. Katzenellenbogen,et al. Highly Selective Salicylketoxime-Based Estrogen Receptor β Agonists Display Antiproliferative Activities in a Glioma Model , 2015, Journal of medicinal chemistry.
[31] Jean-Pierre Marquette,et al. A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy. , 2014, Nature chemical biology.
[32] Asad U Khan,et al. Structure based virtual screening to discover putative drug candidates: necessary considerations and successful case studies. , 2015, Methods.
[33] I. Ghosh,et al. New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors. , 2012, Current pharmaceutical design.
[34] Takashi Okamoto,et al. Identification of Highly Selective and Potent Histone Deacetylase 3 Inhibitors Using Click Chemistry-Based Combinatorial Fragment Assembly , 2013, PloS one.
[35] Sungwoo Hong,et al. Selective and potent small-molecule inhibitors of PI3Ks. , 2014, Future medicinal chemistry.
[36] Adam R. Johnson,et al. Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors. , 2013, Journal of medicinal chemistry.
[37] B. Tidor,et al. Rational Approaches to Improving Selectivity in Drug Design , 2012, Journal of medicinal chemistry.
[38] H. Oki,et al. Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach. , 2014, Journal of medicinal chemistry.
[39] Yukihiro Itoh,et al. Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors. , 2012, Journal of medicinal chemistry.
[40] T. Poulos,et al. Discovery of highly potent and selective inhibitors of neuronal nitric oxide synthase by fragment hopping. , 2009, Journal of medicinal chemistry.
[41] M. Ghadiri,et al. Discovery of potent and selective histone deacetylase inhibitors via focused combinatorial libraries of cyclic alpha3beta-tetrapeptides. , 2009, Journal of medicinal chemistry.
[42] P. Taylor,et al. Click chemistry in situ: acetylcholinesterase as a reaction vessel for the selective assembly of a femtomolar inhibitor from an array of building blocks. , 2002, Angewandte Chemie.
[43] Peng Zhan,et al. Identification of novel SIRT2-selective inhibitors using a click chemistry approach. , 2014, Bioorganic & medicinal chemistry letters.
[44] S. Schreiber,et al. A selective inhibitor and probe of the cellular functions of Jumonji C domain-containing histone demethylases. , 2011, Journal of the American Chemical Society.
[45] Yukihiro Itoh,et al. Small-molecular modulators of cancer-associated epigenetic mechanisms. , 2013, Molecular bioSystems.
[46] P. Cole,et al. A mechanism-based inactivator for histone demethylase LSD1. , 2006, Journal of the American Chemical Society.
[47] Peng Zhan,et al. Multivalent agents: a novel concept and preliminary practice in Anti-HIV drug discovery. , 2013, Current medicinal chemistry.
[48] Benjamin Fabre,et al. Targeting matrix metalloproteinases: exploring the dynamics of the s1' pocket in the design of selective, small molecule inhibitors. , 2014, Journal of medicinal chemistry.
[49] C. Schofield,et al. Targeting histone lysine demethylases — Progress, challenges, and the future , 2014, Biochimica et biophysica acta.
[50] M. Slijper,et al. Development of Selective Bisubstrate‐Based Inhibitors Against Protein Kinase C (PKC) Isozymes By Using Dynamic Peptide Microarrays , 2009, Chembiochem : a European journal of chemical biology.
[51] Andrew J. P. White,et al. Defining the mechanism of action and enzymatic selectivity of psammaplin A against its epigenetic targets. , 2012, Journal of medicinal chemistry.
[52] Peng Zhan,et al. Conformational restriction: an effective tactic in 'follow-on'-based drug discovery. , 2014, Future medicinal chemistry.
[53] S. Knapp,et al. Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains , 2014, Journal of the American Chemical Society.
[54] Qiang Huang,et al. X-ray crystal structure of phosphodiesterase 2 in complex with a highly selective, nanomolar inhibitor reveals a binding-induced pocket important for selectivity. , 2013, Journal of the American Chemical Society.
[55] E. García-Junceda,et al. Exploring the use of conformationally locked aminoglycosides as a new strategy to overcome bacterial resistance. , 2006, Journal of the American Chemical Society.
[56] P. Cole,et al. Mechanistic analysis of a suicide inactivator of histone demethylase LSD1. , 2007, Biochemistry.
[57] Yu-chian Chen. Beware of docking! , 2015, Trends in pharmacological sciences.
[58] Zhe Li,et al. Structure-based discovery of highly selective phosphodiesterase-9A inhibitors and implications for inhibitor design. , 2012, Journal of medicinal chemistry.
[59] H. Oki,et al. Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1″ binding site. , 2014, Bioorganic & medicinal chemistry.
[60] R. Johnstone,et al. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders , 2015, Nature Reviews Drug Discovery.
[61] Yukihiro Itoh,et al. Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors. , 2007, Journal of medicinal chemistry.
[62] T. Poulos,et al. Minimal pharmacophoric elements and fragment hopping, an approach directed at molecular diversity and isozyme selectivity. Design of selective neuronal nitric oxide synthase inhibitors. , 2008, Journal of the American Chemical Society.
[63] K. Kirshenbaum,et al. Tricks with clicks: modification of peptidomimetic oligomers via copper-catalyzed azide-alkyne [3 + 2] cycloaddition. , 2010, Chemical Society reviews.
[64] Takayoshi Suzuki,et al. Inhibition of human sirtuins by in situ generation of an acetylated lysine-ADP-ribose conjugate. , 2009, Journal of the American Chemical Society.
[65] Takayoshi Suzuki,et al. Lysine demethylases inhibitors. , 2011, Journal of medicinal chemistry.
[66] M. Hojjat-Farsangi. Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies , 2014, International journal of molecular sciences.
[67] Richard J. Marhöfer,et al. Docking-based virtual screening of covalently binding ligands: an orthogonal lead discovery approach. , 2013, Journal of medicinal chemistry.
[68] Tao Wang,et al. Fragment-based drug discovery and molecular docking in drug design. , 2015, Current pharmaceutical biotechnology.
[69] P. Taylor,et al. Synthesis of Selective Agonists for the α7 Nicotinic Acetylcholine Receptor with In Situ Click-Chemistry on Acetylcholine-Binding Protein Templates , 2012, Molecular Pharmacology.
[70] A. Nairn,et al. Substrate-based fragment identification for the development of selective, nonpeptidic inhibitors of striatal-enriched protein tyrosine phosphatase. , 2013, Journal of medicinal chemistry.
[71] Takayoshi Suzuki,et al. Epigenetic control using natural products and synthetic molecules. , 2006, Current medicinal chemistry.
[72] Zoran Radić,et al. In situ click chemistry: enzyme inhibitors made to their own specifications. , 2004, Journal of the American Chemical Society.
[73] Kristian Helin,et al. Histone lysine demethylases as targets for anticancer therapy , 2013, Nature Reviews Drug Discovery.
[74] B. Dymock,et al. Selective JAK inhibitors. , 2014, Future medicinal chemistry.
[75] C. Supuran,et al. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? , 2012, Chemical reviews.
[76] Jane R Kenny,et al. Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2. , 2013, Journal of medicinal chemistry.
[77] Ruibo Wu,et al. Computational Design of a Time-Dependent Histone Deacetylase 2 Selective Inhibitor , 2014, ACS chemical biology.
[78] S. Turk,et al. Discovery, biological evaluation, and crystal structure of a novel nanomolar selective butyrylcholinesterase inhibitor. , 2014, Journal of medicinal chemistry.
[79] R. Liskamp,et al. Directed Modulation of Protein Kinase C Isozyme Selectivity with Bisubstrate‐Based Inhibitors , 2012, ChemMedChem.
[80] Janez Konc,et al. Selective inhibitors of aldo-keto reductases AKR1C1 and AKR1C3 discovered by virtual screening of a fragment library. , 2012, Journal of medicinal chemistry.
[81] Kyle V. Butler,et al. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. , 2010, Journal of the American Chemical Society.
[82] Yukihiro Itoh,et al. Lysine-specific demethylase 1-selective inactivators: protein-targeted drug delivery mechanism. , 2013, Angewandte Chemie.
[83] Swati S. More,et al. Discovery of potent and selective sirtuin 2 (SIRT2) inhibitors using a fragment-based approach. , 2014, Journal of medicinal chemistry.
[84] Takayoshi Suzuki,et al. Explorative study on isoform-selective histone deacetylase inhibitors. , 2009, Chemical & pharmaceutical bulletin.
[85] Makoto Hasegawa,et al. Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of jumonji domain-containing protein 2 histone demethylase inhibitors. , 2010, Journal of medicinal chemistry.
[86] Eddy Petit,et al. Carbonic anhydrase-encoded dynamic constitutional libraries: toward the discovery of isozyme-specific inhibitors. , 2009, Journal of medicinal chemistry.
[87] Yukihiro Itoh,et al. Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate. , 2006, Journal of medicinal chemistry.
[88] M. Mathieu,et al. Discovery of (2S)-8-[(3R)-3-methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one: a novel potent and selective inhibitor of Vps34 for the treatment of solid tumors. , 2014, Journal of medicinal chemistry.
[89] S. Grant,et al. Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. , 2014, Pharmacology & therapeutics.
[90] C. Klein,et al. Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments. , 2014, Journal of medicinal chemistry.